Anlon Healthcare
Anlon Healthcare Q1 FY27: Capex ₹130 Cr
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #33 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Anlon Healthcare Q1 FY27 key numbers
- Revenue
- Expansion underway at Anlon with a ₹130 crore CAPEX; capacity expected to increase by 1200 metric tonnes (from 400 to approx. 1600 metric tonnes).
As stated in Anlon Healthcare's Q1 FY27 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.
The short version
FY27 revenue guidance maintained at ₹380 to ₹400 crore, with H1 expected slightly lower than H2. PAT margin expected for FY27 and FY28 is around 12-13%, considered conservative due to potential expansion delays.
From Anlon Healthcare's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- FY27 revenue guidance maintained at ₹380 to ₹400 crore, with H1 expected slightly lower than H2.
- Current optimal capacity utilization is around 65-70%, with peak revenue potential from existing assets at ₹350-400 crore.
- Expansion underway at Anlon with a ₹130 crore CAPEX; capacity expected to increase by 1200 metric tonnes (from 400 to approx. 1600 metric tonnes).
- New capacity at Anlon expected to commission by Q1 FY28, aiming to drive FY28 revenue to approximately ₹700 crore.
- For FY27-28, standalone Anlon sales expected to remain around ₹180 crore, as it is operating near peak capacity.
- Growth also supported by subsidiaries Apiqo and BizoƟc, both profitable with increasing capacities and business opportunities.
- New product launches planned in peptides and pain management (cosmetic peptides and ointments) with production starting by FY28.
2 more points from Anlon Healthcare's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anlon Healthcare said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX for expansion is around ₹130 crore focused on Anlon's standalone capacity expansion.
- The expansion will increase Anlon's capacity by approximately 1,200 metric tons (from current 400 to 1,600 metric tons).
- Construction and statutory approvals are underway, with expected commissioning by Q1 FY28 (subject to regulatory timelines).
- Debt financing of around ₹70 crore is planned for this CAPEX, with the remainder funded internally.
- Anlon Biologics subsidiary is being established for peptides and biologics manufacturing, with operations expected to start generating revenue by FY28 Q4.
- Anlon Medicare, focusing on surgical implants for trauma and orthopedic applications, is expected to generate revenue from FY28 Q2.
2 more points from Anlon Healthcare's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anlon Healthcare said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It is indicated that the company has long-term relationships with 10 to 15 key B2B customers.
- Pricing and payments are based on these long-term contracts, with payment terms generally around 90 days but actual receipts sometimes extending to 130-135 days.
- The company is focusing on strict payment terms and not working with customers who delay payments to improve receivables.
2 more points from Anlon Healthcare's call on order book
Create a free account to keep reading this call
What the Q1 FY27 call signalled
3 of 4 strong
Anlon Healthcare — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹106 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anlon Healthcare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anlon Healthcare and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anlon Healthcare Q1 FY27 results?
FY27 revenue guidance maintained at ₹380 to ₹400 crore, with H1 expected slightly lower than H2. PAT margin expected for FY27 and FY28 is around 12-13%, considered conservative due to potential expansion delays.
What is Anlon Healthcare share price analysis?
Anlon Healthcare currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 38.5 with a market cap of ₹1,217 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anlon Healthcare planning capital expenditure?
Current CAPEX for expansion is around ₹130 crore focused on Anlon's standalone capacity expansion.
Keep Anlon Healthcare on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.